Besponsa (inotuzumab ozogamicin) Intravenous — Coverage Criteria
Defines medical necessity, dosing limits, eligible diagnoses, and authorization requirements for Besponsa (inotuzumab ozogamicin) for EmblemHealth members.
Max units and dosing schedule were replaced with a single limit: 63 billable units every 21 days (for up to a maximum of 6 cycles).
Pediatric ALL criteria were modified to remove Ph-status branching and require BCR::ABL1 negative disease when used with mini-hyper-CVD.
Adult indications updated to add use as frontline consolidation therapy and clarify possible combinations (mini-hyper-CVD ± blinatumomab, or with TKI therapy) with Ph-status conditions.
Limitations now explicitly require that the patient has not previously received inotuzumab ozogamicin and must have CD22-positive disease.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.